| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.015 | 0.7 |
| mRNA | BRD-M00053801 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
| mRNA | SR-II-138A | CTRPv2 | pan-cancer | AAC | -0.01 | 0.7 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | 0.019 | 0.7 |
| mRNA | QS11 | GDSC1000 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | Axitinib | FIMM | pan-cancer | AAC | 0.054 | 0.8 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | -0.015 | 0.8 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | triptolide | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |